Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Recent News

Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer Approved by the FDA
FDA Grants Accelerated Approval to Atezolizumab Combination in Triple-Negative Breast Cancer
FDA Approves New Formulation of Trastuzumab for Subcutaneous Use in Some Breast Cancers
2019 ASCO-SITC: Neoadjuvant Chemotherapy and the Immunologic Landscape in Breast Cancer
Targeting Chemotherapy-Resistant Breast Cancer
Can Oolong Tea Inhibit Growth of Breast Cancer?
Reducing Risk for Invasive Breast Cancer With Low-Dose Tamoxifen
Comparing Breast Irradiation Regimens in Preventing Local Recurrence
Impact of Pathologic Complete Response on Breast Cancer Recurrence and Mortality
Racial Disparities in Breast Cancer Prevention: Focus on Complexity of Gathering Information
FDA Approves Trastuzumab Biosimilar for Treatment of Advanced Breast Cancer
Predictive Biomarker in Metastatic Triple-Negative Breast Cancer
Does Oxybutynin Reduce Hot Flashes in Breast Cancer Survivors?
SOLAR-1: Predicting Response to Alpelisib in PIK3CA-Mutant Breast Cancer
Can Cryoablation ‘Freeze Out’ Low-Risk Breast Cancers?
Shedding Light on Resistance to PARP Inhibitors in Patients With Breast Cancer
Conventional Whole-Breast vs. Partial-Breast Irradiation in Controlling Tumor Recurrence
Should Some Women Younger Than Age 30 Undergo Mammography?
SABCS 2018: Adjuvant Capecitabine for Early-Stage Triple-Negative Breast Cancer
SABCS 2018: Adjuvant Therapies for HER2-Positive Breast Cancer Compared in KATHERINE Trial
FDA Approves Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer
SABCS 2018: Comparing Letrozole With and Without Palbociclib in Metastatic Breast Cancer
Risk Class May Be Linked to Response to Breast Cancer Treatments
SABCS 2018: Novel Tool for Assessing Risk of Chemotherapy Toxicity in Older Patients With Breast Cancer
Rethinking Screening Mammography in Women Aged 75 and Older
SABCS 2018: Duration of Adjuvant Trastuzumab in Early Breast Cancer
SABCS 2018: When to Initiate Adjuvant Chemotherapy in Triple-Negative Breast Cancer
Shorter Course of Trastuzumab in Some HER2-Positive Early Breast Cancers
Machine-Learning Prognostic Risk Model for African American Women With Breast Cancer
Endocrine Therapy on Trial in Male Breast Cancer
HDAC Inhibitor Studied in Treatment of Advanced Breast Cancer
City of Hope Launches CAR T-Cell Trial in Patients With Breast Cancer and Brain Metastases
ESMO 2018: Zoledronic Acid and Letrozole vs. Tamoxifen in Early Breast Cancer
FDA Grants Priority Review to Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ESMO 2018: Targeting the Tumor Genome in Advanced Breast Cancer
ASTRO 2018: Radiation After Surgery for Low-Risk Ductal Carcinoma in Situ
ESMO 2018: Novel Combination Therapy for Advanced Breast Cancer
Novel Regional Anesthesia Technique for Pain Management After Mastectomy
ASTRO 2018: Long-Term Effects of Once-Weekly vs. Conventional Breast Radiation
Active Monitoring for Low-Risk Ductal Carcinoma in Situ
ESMO 2018: Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
MIBC 2018: Evaluating Validity of Online Breast Cancer Risk Assessment Tool
MIBC 2018: Musculoskeletal Side Effects of Breast Reconstructive Surgery
ESMO 2018: Are Women With Early Breast Cancer Adhering to Hormonal Therapy?
Quality Care Symposium: Assessing Delivery of Care for Women With Metastatic Breast Cancer
FDA Approves Talazoparib for Germline BRCA-Mutated HER2-Negative Breast Cancer
Does Adjuvant Bevacizumab Improve Outcomes in HER2-Negative Patients?
Quality Care Symposium: Prevalence of Unnecessary Scans for Early-Stage Breast Cancer
International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers
Quality Care Symposium: Few Women Discuss Financial Aspect of Cancer Care With Physicians
Are Patients Treated for Breast Cancer at Increased Risk of CML?
Polymorphism and Radiation-Induced Fibrosis in Patients With Early-Stage Breast Cancer
How Does Talazoparib Compare With Chemotherapy for Breast Cancer Subgroup?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.